AstraZeneca has confidence in new tension

The head of drug manufacturer AstraZeneca, which is developing a coronavirus vaccine that is widely expected to be approved by the British authorities this week, said on Sunday that researchers believe the shot will be effective against a new variant of the virus that will cause a rapid increase in infections in Britain. Partial results indicate that the AstraZeneca shot is approximately 70% effective in preventing coronavirus infection, compared to the 95% efficacy reported by Pfizer and its German partner BioNTech, reports AP. But CEO Pascal Soriot has expressed confidence in London Sunday Times. “We think we’ve established the winning formula and how to get effectiveness that is after two doses with everyone else out there,” Soriot said. “I can ‘t tell you anymore because we’ll be publishing sometime.”

Asked about the effectiveness of the vaccine against the new variant of the coronavirus that is spreading in the UK, Soriot said: “So far we think the vaccine should remain effective. But we can not be sure, so we’re going to test it. “BioNTech has expressed similar confidence in the vaccine it has developed with Pfizer. AstraZeneca has developed its vaccine, the Phase 3 clinical trials of which are now being reviewed by UK regulators, with The University of Oxford. said it offers ‘100% protection’ against serious COVID-19 cases – those in need of hospitalization, according to the Times of Israel. The UK government has ordered 100 million doses of AstraZeneca’s vaccine; 40 million of them are on track to be delivered by the end of March. (The company’s vaccine was in doubt.)